[1] |
World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
|
[2] |
World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
|
[3] |
Liu Z, Dong H, Wu B, et al. Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings. J Infect, 2019, 79(4):349-356. doi:10.1016/j.jinf.2019.08.004.
pmid: 31400354
|
[4] |
Furin J, Cox H, Pai M. Tuberculosis. Lancet, 2019, 393(10181):1642-1656. doi:10.1016/S0140-6736(19)30308-3.
pmid: 30904262
|
[5] |
Pan Y, Yu Y, Yi Y, et al. The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: a retrospective study. BMC Infect Dis, 2023, 23(1):162. doi:10.1186/s12879-023-08130-1.
pmid: 36922787
|
[6] |
Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet, 2004, 363(9407):474-481. doi:10.1016/S0140-6736(04)15496-2.
pmid: 14962530
|
[7] |
中华人民共和国国家卫生健康委员会. 中国结核病预防控制工作技术规范(2020年版). 国卫办疾控函〔2020〕279号. 2020-04-02.
|
[8] |
Jain K, Desai M, Solanki R, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother, 2014, 5(2):145-149. doi:10.4103/0976-500X.130062.
pmid: 24799815
|
[9] |
Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One, 2009, 4(9):e6914. doi:10.1371/journal.Pone.0006914.
|
[10] |
Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax, 2006, 61(2):158-163. doi:10.1136/thx.2005.045963.
pmid: 16254056
|
[11] |
Duraisamy K, Mrithyunjayan S, Ghosh S, et al. Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India. Ann Am Thorac Soc, 2014, 11(5):712-718. doi:10.1513/AnnalsATS.201312-447OC.
pmid: 24735096
|
[12] |
Jeon DS, Shin DO, Park SK, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci, 2011, 26(1):33-41. doi:10.3346/jkms.2011.26.1.33.
pmid: 21218027
|
[13] |
郝晓晖, 姚岚, 孙华, 等. 老年耐多药肺结核临床特征及转归分析. 中华结核和呼吸杂志, 2014, 37(3):188-191. doi:10.3760/cma.j.issn.1001-0939.2014.03.009.
|
[14] |
Yamaguchi Y, Kawabe Y, Nagayama N, et al. A study on the clinical features of pulmonary tuberculosis in elderly patients. Kekkaku, 2001, 76(6): 447-454. doi:10.11400/kekkaku1923.76.447.
|
[15] |
Das SK, Mukherjee RS, Ghosh IN, et al. A study of pulmonary tuberculosis in the elderly. J Indian Med Assoc, 2007, 105(8):432-439.
pmid: 18236905
|
[16] |
World Health Organization. Global tuberculosis report 2012. Geneva: World Health Organization, 2012.
|
[17] |
Kwon YS, Chi SY, Oh IJ, et al. Clinical characteristics and treatment outcomes of tuberculosis in the elderly: a case control study. BMC Infect Dis, 2013, 13:121. doi:10.1186/1471-2334-13-121.
pmid: 23510403
|
[18] |
李硕兰, 李明武, 李光妹, 等. 中国耐多药肺结核不良治疗转归影响因素的Meta分析. 中国防痨杂志, 2022, 44(12):1303-1313. doi:10.19982/j.issn.1000-6621.20220212.
|
[19] |
张梦娴, 杨成凤, 叶建君, 等. 1447例耐多药肺结核患者治疗转归队列分析. 公共卫生与预防医学, 2020, 31(3):68-72. doi:10.3969/j.issn.1006-2483.2020.03.017.
|
[20] |
徐彩红, 张慧, 阮云洲, 等. 我国六省(自治区)全球基金项目地区耐多药肺结核诊疗效果的回顾性分析. 中国防痨杂志, 2018, 40(6):559-563. doi:10.3969/j.issn.1000-6621.2018.06.003.
|
[21] |
王坚杰, 易凤莲, 陈聪, 等. 团体心理辅导对耐多药结核病患者的抑郁症状干预效果. 公共卫生与预防医学, 2017, 28(1):50-52.
|
[22] |
唐神结, 肖和平, 张青. 耐多药结核病化疗研究的新进展. 中华结核和呼吸杂志, 2009, 32(8):617-620. doi:10.3760/cma.j.issn.1001-0939.2009.08.019.
|
[23] |
杨超, 王晶, 唐桂林, 等. 2016—2020年北京市通州区病原学阴性肺结核流行特征及治疗转归分析. 结核与肺部疾病杂志, 2022, 3(6):477-482. doi:10.19983/j.issn.2096-8493.20220149.
|
[24] |
何伏华, 冯地忠, 丁守华. 2013—2017年淮安市菌阴肺结核流行特征分析. 中国校医, 2019, 33(3):196-197,204.
|
[25] |
雷蓉蓉, 汪清雅, 张婷. 重庆市肺结核患者复发情况及影响因素分析. 中国热带医学, 2020, 20(11):1092-1095. doi:10.13604/j.cnki.46-1064/r.2020.11.16.
|
[26] |
戴志松, 陈堃, 林淑芳, 等. 福建省成功治疗的肺结核患者10年复发情况及影响因素分析. 疾病监测, 2021, 36(11):1152-1158. doi:10.3784/jbjc.202106300378.
|
[27] |
Liu Q, Lu P, Martinez L, et al. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. BMC Infect Dis, 2018, 18(1):114. doi:10.1186/s12879-018-3021-0.
pmid: 29510666
|
[28] |
Nagaraja C, Shashibhushan BL, Asif M, et al. Pattern of drug-resistance and treatment outcome in multidrug-resistant pulmonary tuberculosis. Indian J Chest Dis Allied Sci, 2012, 54(1):23-26.
pmid: 22779119
|
[29] |
Jain K, Desai M, Solanki R, et al. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother, 2014, 5(2):145-149. doi:10.4103/0976-500X.130062.
pmid: 24799815
|
[30] |
Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med, 2006, 144(9):650-659. doi:10.7326/0003-4819-144-9-200605020-00008.
pmid: 16670134
|
[31] |
Kurbatova EV, Gammino VM, Bayona J, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2012, 16(10):1335-1343. doi:10.5588/ijtld.11.0811.
pmid: 23107633
|
[32] |
Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med, 2015, 3(3):201-209. doi:10.1016/S2213-2600(15)00036-3.
pmid: 25726085
|
[33] |
Basit A, Ahmad N, Khan AH, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLoS One, 2014, 9(4):e93206. doi:10.1371/journal.pone.0093206.
|
[34] |
Singla R, Sarin R, Khalid UK, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis, 2009, 13(8):976-981.
pmid: 19723377
|
[35] |
Rodriguez M, Monedero I, Caminero JA, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis, 2013, 17(4):520-525. doi:10.5588/ijtld.12.0481.
pmid: 23485386
|
[36] |
林志浩, 丘小燕, 马晓慧, 等. 佛山市193例耐多药肺结核患者的治疗转归及影响因素分析. 实用预防医学, 2022, 29(11):1290-1294.
|